Pipeline Insight: Antihypertensives - Weak pipeline leaves innovation to Novartis

Questions: Discounts, Updates etc.

Price: $11,400.00

Publication Date: 2006-03-31

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Despite modest improvements in blood pressure control, effective blood pressure control for all still seems to be an elusive goal. As such, the promotion and use of combination therapies has increased, explaining much of the current R&D activity in this area where many developers are studying novel combinations of currently marketed drugs rather than discovering innovative treatments


Scope

  • Evaluation of patient potential for developmental antihypertensives over the period 2006-2015
  • Scrutiny of key impacts on the R&D approach and cost, evaluation of optimal clinical trial end points and identification of suitable comparators
  • Evaluation of key players in the hypertensive market and opposing company approaches to development and commercialization
  • Analysis of key antihypertensive drugs in development and their ability to satisfy major unmet needs and compete with existing agents


    • Report Highlights
    The use of fixed dose combination (FDC) therapy will continue to grow substantially over the forecast period, exceeding the growth of single pill alternatives. Despite FDCs forming an essential part of a strategy for controlling hypertension, their development is starving innovation within antihypertensive R&D

    Rasilez, the only real innovation in the current pipeline, will be the first oral renin inhibitor to be launched. Its ability to proximally block the renin angiotensin system (RAS), combined with its true 24-hour activity, means it may offer specific advantages over other drug classes, and is likely to become a blockbuster by 2010

    Despite continued research into other hypertension targets such as endothelin and vasopeptidase poor safety records, lack of efficacy compared to other classes and a low patient potential, these agents promise to be no more than an academic interest rather than providing physicians with a real alternative in treating hypertension


    Reasons to Purchase

  • Understand physician sentiment on renin inhibitors as the next innovative drug class, and the threats faced by existing and developmental products
  • View independent sales forecasts for products in late stage development for treatment of hypertension in both existing and novel classes
  • Identify early stage antihypertensive compounds with high potential being developed by companies seeking a marketing partner

    • Table of Contents

    Other users found this report page using the following search terms: hypertension antihypertensive blood pressure ace arb pipeline novartis antihypertensives hypertension drugs swot antihypertensive analysis clinical sales

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.